Credit Suisse Maintains Vertex Pharmaceuticals Incorporated to Outperform with Price Target $112.00

Brokerage firm Credit Suisse Maintains its rating on Vertex Pharmaceuticals Incorporated(NASDAQ:VRTX). In a research note issued to the investors, the brokerage major Lowers the price-target to $112.00 per share. The shares have been rated Outperform. The rating by Credit Suisse was issued on Apr 11, 2016.

In a different note, On Mar 8, 2016, Leerink Swann said it Maintains its rating on Vertex Pharmaceuticals Incorporated. In the research note, the firm Lowers the price-target to $131.00 per share. The shares have been rated ‘Outperform’ by the firm. On Feb 11, 2016, Oppenheimer said it Assumes its rating on Vertex Pharmaceuticals Incorporated. The shares have been rated ‘Perform’ by the firm. Leerink Swann said it Initiates Coverage on Vertex Pharmaceuticals Incorporated, according to a research note issued on Feb 5, 2016. The shares have been rated ‘Outperform’ by the firm. On Feb 1, 2016, Jefferies said it Upgrades its rating on Vertex Pharmaceuticals Incorporated. The shares have been rated ‘Buy’ by the firm. On Jan 28, 2016, Barclays said it Maintains its rating on Vertex Pharmaceuticals Incorporated. In the research note, the firm Lowers the price-target to $150.00 per share. The shares have been rated ‘Overweight’ by the firm. Credit Suisse said it Initiates Coverage on Vertex Pharmaceuticals Incorporated, according to a research note issued on Jan 20, 2016. In the research note, the firm Announces the price-target to $151 per share. The shares have been rated ‘Outperform’ by the firm.

Vertex Pharmaceuticals Incorporated (VRTX) shares turned negative on Fridays trading session with the shares closing down -5.33 points or -6.12% at a volume of 41,63,741. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $87.6. The peak price level was also seen at $87.6 while the days lowest was $81.02. Finally the shares closed at $81.75. The 52-week high of the shares is $143.45 while the 52-week low is $75.9. According to the latest information available, the market cap of the company is $20,143 M.

Vertex Pharmaceuticals Incorporated(VRTX) last announced its earnings results on Jan 27, 2016 for Fiscal Year 2015 and Q4.Company reported revenue of $417.94M. Analysts had an estimated revenue of $405.57M. Earnings per share were $0.17. Analysts had estimated an EPS of $0.16.

Several Insider Transactions has been reported to the SEC. On Apr 8, 2016, Joshua S Boger (director) sold 5,130 shares at $89.20 per share price.Also, On Feb 4, 2016, Ian F Smith (EVP & CFO) sold 12,084 shares at $91.32 per share price.On Feb 4, 2016, Paul M Silva (SVP & Corp Controller) sold 5,062 shares at $91.63 per share price, according to the Form-4 filing with the securities and exchange commission.

Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering developing manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertex’s business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs including programs in the areas of oncology and neurology. The Company’s product candidates include KALYDECO (ivacaftor) Lumacaftor in combination with Ivacaftor VX-661 in combination with Ivacaftor VX-803 VX-970 and VX-222. The Company’s product KALYDECO is available in the market.

Leave a Reply

Vertex Pharmaceuticals Incorporated - Is it time to Sell?

Top Brokerage Firms are advising their investors on Vertex Pharmaceuticals Incorporated. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.